Mary Wilson
Well-known member
Michael K. Lo, C?sar G. Albari?o, Jason K. Perry, Silvia Chang, Egor P. Tchesnokov, Lisa Guerrero, Ayan Chakrabarti, Punya Shrivastava-Ranjan, Payel Chatterjee, Laura K. McMullan, Ross Martin, Robert Jordan, Matthias G?tte, Joel M. Montgomery, Stuart T. Nichol, Mike Flint, Danielle Porter, and Christina F. Spiropoulou
PNAS first published October 7, 2020;
https://doi.org/10.1073/pnas.2012294117
Edited by Peter Palese, Icahn School of Medicine at Mount Sinai, New York, NY, and approved September 7, 2020 (received for review June 14, 2020)
Remdesivir is a nucleotide analog prodrug that has been evaluated in humans against acute Ebola virus disease; it also recently received emergency use authorization for treating COVID-19. For antiviral product development, the Food and Drug Administration recommends the characterization of in vitro selected resistant viruses to define the specific antiviral mechanism of action. This study identified a single amino acid residue in the Ebola virus polymerase that conferred low-level resistance to remdesivir.
https://www.pnas.org/content/early/2020/10/06/2012294117
PNAS first published October 7, 2020;
https://doi.org/10.1073/pnas.2012294117
Edited by Peter Palese, Icahn School of Medicine at Mount Sinai, New York, NY, and approved September 7, 2020 (received for review June 14, 2020)
Remdesivir is a nucleotide analog prodrug that has been evaluated in humans against acute Ebola virus disease; it also recently received emergency use authorization for treating COVID-19. For antiviral product development, the Food and Drug Administration recommends the characterization of in vitro selected resistant viruses to define the specific antiviral mechanism of action. This study identified a single amino acid residue in the Ebola virus polymerase that conferred low-level resistance to remdesivir.
https://www.pnas.org/content/early/2020/10/06/2012294117